Mesoblast Secures CAR Technology License
Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, announced on April 14, 2026, that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This acquisition targets the precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products, according to GlobeNewswire PE. Mesoblast plans to incorporate engineered CARs to boost the effectiveness of its products by enhancing target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.
Details of the Technology and Development
The CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering. Mesoblast’s MSC technology platforms include the first and only FDA-approved MSC product in the U.S., designed for treating tissue-specific inflammatory diseases due to their homing capabilities and immunomodulatory properties. The technology aims to enhance targeted homing to inflamed tissue, increasing potency for conditions such as ulcerative colitis, Crohn’s disease, Lupus Nephritis, and other B cell autoimmune diseases, as outlined in the announcement from GlobeNewswire PE.
Acquisition Execution and Support
Mesoblast obtained the worldwide exclusive rights to the CAR-MSC intellectual property by acquiring a startup formed to advance the technology developed at Mayo Clinic. The acquisition was accomplished through the issuance of ASX ordinary shares. As part of the exclusive license, Mayo Clinic will provide in-kind support, including activities related to further advancing the technology and GMP manufacturing. Silviu Itescu, Chief Executive of Mesoblast, stated: ‘This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications.‘
Mesoblast’s Focus on Cellular Medicines
Mesoblast is a world leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform involves therapies that release anti-inflammatory factors to counter and modulate multiple effector arms of the immune system. This acquisition aligns with their ongoing efforts in this area, according to GlobeNewswire PE. As widely-known context, allogeneic cellular medicines represent a growing field in biotechnology, focusing on off-the-shelf treatments for complex diseases.
